Changes of CD4/CD8 ratio and interleukin-16 in systemic lupus erythematosus

被引:22
作者
Matsushita, M
Hayashi, T
Ando, S
Sekigawa, I
Iida, N
Hashimoto, H
Hirose, S
机构
[1] Juntendo Univ, Izu Nagaoka Hosp, Dept Med, Shizuoka 4102295, Japan
[2] Juntendo Univ, Sch Med, Dept Internal Med & Rheumatol, Tokyo 113, Japan
关键词
CD4(+)/CD8(+) T-cell ratio; interleukin-16; systemic lupus erythematosus; T-cell activation;
D O I
10.1007/PL00011171
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The authors investigated changes in the ratio of CD4(+) to CD8(+) T cells (CD4/CD8 ratio) and T-cell activation, indicated by human leukocyte antigen (HLA)-DR expression, in patients with systemic lupus erythematosus (SLE) following treatment. An increase was observed in the CD4/CD8 ratio as well as a decrease in the expression of HLA-DR on T cells with the improvement of clinical manifestations on treatment with steroids or cyclosporine (CSA). Tn addition, steroid treatment suppressed whereas CSA treatment exerted no perceptible influence on the serum interleukin (IL)-16 level, concurrent with changes in T-cell phenotypes. This indicated that the mechanism of the change in the CD4/CD8 ratio differed depending on the drug, and CD8(+) T cells could play an important role in reducing this ratio. The CD4/CD8 ratio and HLA-DR expression may be good indicators of therapeutic efficacy in some SLE patients.
引用
收藏
页码:270 / 274
页数:5
相关论文
共 20 条
[1]   LYMPHOCYTE-T SUBSETS IN SYSTEMIC LUPUS-ERYTHEMATOSUS - CORRELATIONS WITH CORTICOSTEROID-THERAPY AND DISEASE-ACTIVITY [J].
BAKKE, AC ;
KIRKLAND, PA ;
KITRIDOU, RC ;
QUISMORIO, FP ;
REA, T ;
EHRESMANN, GR ;
HORWITZ, DA .
ARTHRITIS AND RHEUMATISM, 1983, 26 (06) :745-750
[2]   Interleukin 16 and its function as a CD4 ligand [J].
Center, DM ;
Kornfeld, H ;
Cruikshank, WW .
IMMUNOLOGY TODAY, 1996, 17 (10) :476-481
[3]  
EMLEN W, 1994, J IMMUNOL, V152, P3685
[4]   HLA-DP+ T-CELLS AND DEFICIENT INTERLEUKIN-2 PRODUCTION IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
HISHIKAWA, T ;
TOKANO, Y ;
SEKIGAWA, I ;
ANDO, S ;
TAKASAKI, Y ;
HASHIMOTO, H ;
HIROSE, S ;
OKUMURA, K ;
ABE, M ;
SHIRAI, T .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1990, 55 (02) :285-296
[5]  
HOROWITZ DA, 1997, T LYMPHOCYTES NATURA, P155
[6]  
Lee S, 1998, BRIT J RHEUMATOL, V37, P1334
[7]   CORRECTION OF INTERLEUKIN-2 PRODUCTION IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS BY REMOVAL OF SPONTANEOUSLY ACTIVATED SUPPRESSOR CELLS [J].
LINKERISRAELI, M ;
BAKKE, AC ;
QUISMORIO, FP ;
HORWITZ, DA .
JOURNAL OF CLINICAL INVESTIGATION, 1985, 75 (02) :762-768
[8]  
LINKERISRAELI M, 1988, J RHEUMATOL, V15, P952
[9]  
Maeda N, 1999, SCAND J RHEUMATOL, V28, P166
[10]   2 DISTINCT SUBSETS OF PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
MCINERNEY, MF ;
CLOUGH, JD ;
SENITZER, D ;
CATHCART, MK .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1988, 49 (01) :116-132